Author

Jessica Hernández

Observed names: Jessica Hernandez, Jessica Hernandez Marrero, Jessica Hernandez-Marrero, Jessica Hernandez–Marrero, Jessica Hernández-Marrero

Institution: University of Puerto Rico System

Observed institutions: University of Puerto Rico, Medical Sciences Campus, University of Puerto Rico System

ORCID: 0000-0003-2192-5216

Observed ORCID: 0000-0003-2192-5216

OpenAlex ID: A5101701512

Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis

2018 · Marcia Cruz-Correa, Linda M. Hylind, et al. · Gastroenterology · 124

Ethnic and Sex Disparities in Colorectal Neoplasia Among Hispanic Patients Undergoing Screening Colonoscopy

2012 · Liselle Lathroum, Fernando Ramos–Mercado, et al. · Clinical Gastroenterology and Hepatology · 19

Ubiquitous neurocognitive dysfunction in familial adenomatous polyposis: proof-of-concept of the role of APC protein in neurocognitive function

2020 · Marcia Roxana Cruz-Correa, Ana Cecilia Sala, et al. · Hereditary Cancer in Clinical Practice · 11

Type 2 diabetes mellitus and colorectal neoplasia risk in Hispanics: a case–control study

2015 · Yaritza Díaz-Algorri, María Eugenia Lozada, et al. · Journal of Diabetes and its Complications · 8

Clinical characterization and mutation spectrum in Hispanic families with adenomatous polyposis syndromes

2013 · Marcia Cruz-Correa, Yaritza Diaz-Algorri, et al. · Familial Cancer · 8

Establishment of a Mesoamerican–Caribbean South–South Research Platform: Challenges in the Meriva (Curcuminoids) Gastric Cancer Chemoprevention Trial

2024 · Eleazar E. Montalvan-Sanchez, Jessica Hernandez-Marrero, et al. · Cancer Prevention Research · 6

Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

2026 · Maria Gonzalez-Pons, Ricardo L. Dominguez, et al. · Cancer Prevention Research · 3

Planning for the unexpected: Strategies for maintaining a robust clinical trial program

2020 · Lemuel F. Melecio Rodríguez, Jessica Hernandez, et al. · Contemporary Clinical Trials Communications · 2

1145 Evaluation of the Safety and Efficacy of Eflornithine (difluoromethylornithine, Dfmo) in Patients With Gastric Premalignant Conditions in the High Incidence Areas of Latin America

2024 · Douglas R. Morgan, Ricardo L. Dominguez, et al. · Gastroenterology · 1

Supplementary Table S5 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Table S9 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Figure S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Table S4 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Data from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Table S1 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Table S7 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Table S1 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

2026 · Maria Gonzalez-Pons, Ricardo L. Dominguez, et al.

Supplementary Figure S2 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

2026 · Maria Gonzalez-Pons, Ricardo L. Dominguez, et al.

Supplementary Table S3 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Data from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

2026 · Maria Gonzalez-Pons, Ricardo L. Dominguez, et al.

Supplementary Table S11 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Figure S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

2026 · Maria Gonzalez-Pons, Ricardo L. Dominguez, et al.

Supplementary Table S4 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

2026 · Maria Gonzalez-Pons, Ricardo L. Dominguez, et al.

Supplementary Table S2 from Safety and Efficacy of Eflornithine in Patients with Gastric Precancerous Lesions: A Double-Blinded, Randomized Clinical Trial

2026 · Douglas R. Morgan, Ricardo L. Dominguez, et al.

Supplementary Figure S3 from Randomized, Double-Blind, Placebo-Controlled Trial of Meriva (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

2026 · Maria Gonzalez-Pons, Ricardo L. Dominguez, et al.

Works count: 42

Citation count: 182

H-index: 6

I10-index: 3